Library
Coverage
5 items- Sirius: $50 Million Series B2 Raised For Advancing Novel siRNA Therapeutics For Cardiometabolic Disorderspulse2.com/sirius-50-million-series-b2-raised-for-advancing-novel-sirna-therapeutics-for-cardiometabolic-disorders/
Sirius Therapeutics secures $50 million in Series B2 funding to advance its novel siRNA-based therapies targeting cardiometabolic disorders. The round includes participation from BioTrack Capital as a new investor, alongside returning backers OrbiMed, Creacion Ventures, and Hankang Capital, alongside an unnamed corporate venture firm. Proceeds will support clinical development and further innovation in RNA delivery technologies.
May 2025Pulse 2.0News article
- Odyssey Therapeutics Announces $101 Million Series C Financingodysseytx.com/odyssey-therapeutics-announces-101-million-series-c-financing/
Odyssey Therapeutics secures **$101 million in Series C funding** to advance its precision immunomodulators and oncology medicines. The round is led by **Ascenta Capital**, with participation from investors including **OrbiMed, SR One, General Catalyst**, and others. The company focuses on next-generation therapies targeting immune system modulation for cancer treatment.
Dec 2023OdysseyNews article
- Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financingprnewswire.com/news-releases/odyssey-therapeutics-announces-oversubscribed-168-million-series-b-financing-301647627.html
Odyssey Therapeutics secures a fully subscribed $168 million in Series B funding to advance its precision immunomodulators and oncology treatments. The company develops next-generation therapies targeting immune system modulation for cancer patients. This financing reflects strong investor confidence in its pipeline of experimental medicines.
Oct 2022PR NewswireNews article
- Covington Represents Odyssey Therapeutics in $218M Series A Financingcov.com/en/news-and-insights/news/2021/12/covington-represents-odyssey-therapeutics-in-218m-series-a-financing
Odyssey Therapeutics secures **$218 million in Series A funding** to advance its next-generation biotechnology innovations. The company, specializing in cutting-edge therapeutic solutions, partners with law firm **Covington** for the financing round. This capital supports research and development in its core pipeline of experimental treatments.
Dec 2021Covington & Burling LLPNews article
